HENDERSON, Nev., Nov. 29, 2017 -- United Health Products, Inc. (UHP) (OTC:UEEC), a manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that its South African distributor, SSEM Mthembu Medical (SSEM), has notified UHP that they have approved HemoStyp to be marketed in South Africa. SSEM has placed its first order for the product with UHP.
The approval is for applications for wounds that have breached the dermis and where the wounds can only heal by secondary intent. The applications include severe wounds that have extensively breached the dermis, and healing is by secondary intent (by granulation from the base of the wound). Examples: dressings for chronic extensive ulcerated wounds, severe burns, severe decubitus wounds, or dressings providing a temporary skin substitute.
SSEM Mthembu Medical (Pty) Ltd. is a distributor of electro-medical devices and medical consumables throughout Southern Africa.
SSEM Mthembu Medical provides specialised equipment to meet the stringent expectations of specialist physicians, private clinics and hospitals - including operating theatres, critical care, high care units, trauma and emergency care. The company also caters for the occupational health and home care sectors.
About United Health Products, Inc.
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
| Company Contact: | IR Contact: | |
| United Health Products Inc. | PAN Consultants LTD | |
| 877-358-3444 | 212-344-6464 |


OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Instagram Outage Disrupts Thousands of U.S. Users
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 



